Emboline

Executive Summary

Emboline, based in Santa Cruz, CA, is a private medical device company pioneering the Emboliner® Total-Body Embolic Protection System. Designed for use during interventional heart procedures such as transcatheter aortic valve replacement (TAVR) and percutaneous coronary intervention (PCI), the system captures and removes embolic debris released into the bloodstream, which can cause stroke, cognitive decline, acute kidney injury, and other ischemic complications. By providing total-body protection, Emboliner addresses a critical unmet need in cardiovascular interventions where existing embolic protection devices are limited to specific vascular territories. The company's technology has the potential to reduce the incidence of post-procedural adverse events, improving patient outcomes and lowering healthcare costs associated with managing complications. Emboline operates in the rapidly growing cardiovascular device market, driven by an aging population and increasing adoption of minimally invasive procedures. Currently at an early commercial or pre-commercial stage, Emboline has not disclosed funding or revenue details. The company's success hinges on regulatory clearance, clinical evidence, and market adoption. If the Emboliner demonstrates superior safety and efficacy, it could become the standard of care for embolic protection, attracting partnerships with major cardiovascular device firms or acquisition interest. However, competition from established players and regulatory hurdles present risks. Emboline's innovative approach and the large addressable market support a positive outlook, but execution and funding remain key uncertainties.

Upcoming Catalysts (preview)

• H2 2026FDA 510(k) Clearance for Emboliner System70% success
• H1 2027Publication of Pivotal Clinical Trial Results60% success
• H2 2026Strategic Partnership or Licensing Deal with a Major Cardiovascular Company50% success